Suzhou Ribo Life Science Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Suzhou Ribo Life Science Co., Ltd. - overview
Established
2007
Location
Suzhou, Jiangsu, China
Primary Industry
Pharmaceuticals
About
Based in Suzhou, China and founded in 2007, Suzhou Ribo Life Science Co. , Ltd. is a biopharmaceutical engaged in the research and development of RNAi technologies and oligonucleotide therapeutics. In August 2020, the company received the approval of clinical trials for new drug treatment of metastatic prostate cancer.
In February 2022, it established an international R&D center in Gothenburg, Sweden. In August 2020, Suzhou Ribo Life Science Co. , Ltd. was converted into a joint stock company.
In January 2026, the company raised HKD 1. 83 billion in an IPO, selling 31. 61 million shares at HKD 57. 97 apiece on the Hong Kong Exchanges and Clearing (HKEX) under the ticker "6938".
Suzhou Ribo Life Science Co. , Ltd. specializes in developing oligonucleotide drugs based on RNA interference (RNAi) technology, focusing on cardiovascular, metabolic, renal and liver diseases, as well as other therapeutic areas. The company's core products include RBD4059, an siRNA (small interfering RNA) drug that targets thrombotic diseases; RBD1016, an siRNA drug for patients with chronic hepatitis B Virus (“HBV”) infection, and other drug candidates for hereditary angioedema and inflammatory diseases.
The company generates revenue from developing and commercializing oligonucleotide drugs globally.
Current Investors
Legend Capital, Legend Star, V Star Capital
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development, Molecular Chemicals
Website
www.ribolia.com
Verticals
HealthTech, Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.